Ezetimibe plus moderate-intensity statin versus high-intensity statin
- PMID: 36813278
- DOI: 10.1136/dtb.2023.000008
Ezetimibe plus moderate-intensity statin versus high-intensity statin
Abstract
Overview of: Kim BK, Hong SJ, Lee YJ, et al Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet 2022;400:380-390.
Keywords: Drug-Related Side Effects and Adverse Reactions; Health Care Quality, Access, and Evaluation.
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical